Riitta Mäkitaro

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)

Noel G. McElvaney, Jonathan Burdon, Mark Holmes et al. · The Lancet Respiratory Medicine · 2016 · 191 citations · Full text

Open-label Extension Trial, Long-term Efficacy, Immunology +2

Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.

Heikki Joensuu, Anu Anttonen, Minna Eriksson et al. · PubMed · 2002 · 165 citations

Tumor Biology, Serum Bfgf, Medicine +14

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.

S Ylisirniö, Matti Höyhtyä, Riitta Mäkitaro et al. · PubMed · 2001 · 77 citations

Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis

Jaana Kaunisto, Katariina Kelloniemi, Eva Sutinen et al. · BMC Pulmonary Medicine · 2015 · 56 citations · Full text